The Zhitong Finance App learned that Deqi Pharmaceutical-B (06996) rose by more than 7%. As of press release, it had risen 7.39% to HK$4.36, with a turnover of HK$7.617,900.
According to the news, recently, Deqi Pharmaceutical-B announced that Antengene Biologics Limited (the authorized party, a wholly-owned subsidiary of the company) and a company newly established by K2 Therapeutics (K2) (the licensee) have entered into an exclusive and sublicensable licensing agreement (license agreement) for ATG-106 (a CDH6×CD3 bispecific T-cell adaptor (TCE)) targeting solid tumors. Dongwu Securities believes that the core of competition for next-generation TCE is to balance efficacy, safety, tolerability, and coverage of targets with low expression/difficult to treat, and global platform capabilities with this capability are still scarce.
Dongwu Securities pointed out that with the differentiated design of “spatial barrier masking+proprietary CD3 sequence”, Deqi Pharmaceutical-B efficiently removes pathogenic cells while significantly reducing the risk of CRS. It has entered the first tier of second-generation TCE in the world, and can be flexibly expanded across the fields of cancer and autoimmunity. In 2026, the company successively authorized ATG-201 (CD19 × CD3) to UCB (60 million USD down payment+20 million USD recent milestone+maximum USD 1.1 billion milestone+tiered royalties), and ATG-106 and other authorized K2 Therapeutics (potentially up to US$1.921 billion transaction consideration cooperation), and the platform entered a continuous BD cashing period.